[go: up one dir, main page]

AR124542A1 - Métodos de tratamiento - Google Patents

Métodos de tratamiento

Info

Publication number
AR124542A1
AR124542A1 ARP210103706A ARP210103706A AR124542A1 AR 124542 A1 AR124542 A1 AR 124542A1 AR P210103706 A ARP210103706 A AR P210103706A AR P210103706 A ARP210103706 A AR P210103706A AR 124542 A1 AR124542 A1 AR 124542A1
Authority
AR
Argentina
Prior art keywords
solvate
hydrate
parenteral
ylethoxy
methylpyrazol
Prior art date
Application number
ARP210103706A
Other languages
English (en)
Inventor
Brandon James Walsh
John W Adams
Prodromos Anthopoulos
Kathe Lynn Stauber
Original Assignee
Arena Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arena Pharm Inc filed Critical Arena Pharm Inc
Publication of AR124542A1 publication Critical patent/AR124542A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se proporcionan métodos para el uso parenteral de 3-metoxi-N-[3-(2-metilpirazol-3-il)-4-(2-morfolin-4-iletoxi)fenil]benzamida, o una sal, hidrato o solvato farmacéuticamente aceptable de este, y el uso secuencial de formulaciones parenterales y orales de 3-metoxi-N-[3-(2-metilpirazol-3-il)-4-(2-morfolin-4-iletoxi)fenil]benzamida, o una sal, hidrato o solvato farmacéuticamente aceptable de este. Reivindicación 50: Una formulación farmacéutica para la administración parenteral que comprende una solución esterilizada que comprende aproximadamente 1 mg/mL a aproximadamente 25 mg/mL (concentración de base libre ajustada) de Compuesto 1, o una sal, hidrato o solvato farmacéuticamente aceptable de este.
ARP210103706A 2020-12-31 2021-12-30 Métodos de tratamiento AR124542A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063133160P 2020-12-31 2020-12-31

Publications (1)

Publication Number Publication Date
AR124542A1 true AR124542A1 (es) 2023-04-05

Family

ID=82260959

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP210103706A AR124542A1 (es) 2020-12-31 2021-12-30 Métodos de tratamiento

Country Status (7)

Country Link
US (1) US20240058350A1 (es)
EP (1) EP4271375A4 (es)
JP (1) JP2024502821A (es)
AR (1) AR124542A1 (es)
CA (1) CA3206840A1 (es)
TW (1) TW202241446A (es)
WO (1) WO2022147318A1 (es)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SA05260357B1 (ar) * 2004-11-19 2008-09-08 ارينا فارماسيتو تيكالز ، أنك مشتقات 3_فينيل_بيرازول كمعدلات لمستقبل سيروتينين 5_ht2a مفيدة في علاج الاضطرابات المتعلقه به
USRE45337E1 (en) * 2006-05-18 2015-01-13 Arena Pharmaceuticals, Inc. Ethers, secondary amines and derivatives thereof as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto
US8084475B2 (en) * 2009-12-04 2011-12-27 Intermune, Inc. Pirfenidone therapy and inducers of cytochrome P450
US8980891B2 (en) * 2009-12-18 2015-03-17 Arena Pharmaceuticals, Inc. Crystalline forms of certain 3-phenyl-pyrazole derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto
JP2014511382A (ja) * 2011-02-23 2014-05-15 コエルルウス リミテッド フルマゼニル錯体、それを含む組成物、およびその使用
EP2780012A4 (en) * 2011-11-18 2015-07-29 Apotex Technologies Inc Methods of treatment with deferiprone
RU2727022C2 (ru) * 2013-10-01 2020-07-17 Сфинготек Гмбх Способ прогнозирования риска возникновения тяжелых нежелательных сердечных явлений
EP3094381A4 (en) * 2014-01-17 2017-10-25 President and Fellows of Harvard College Platelet decoys and use thereof

Also Published As

Publication number Publication date
WO2022147318A1 (en) 2022-07-07
EP4271375A4 (en) 2024-11-20
TW202241446A (zh) 2022-11-01
US20240058350A1 (en) 2024-02-22
JP2024502821A (ja) 2024-01-23
EP4271375A1 (en) 2023-11-08
CA3206840A1 (en) 2022-07-07

Similar Documents

Publication Publication Date Title
AR029174A1 (es) Derivados de espirooxindol, proceso para su preparacion, formulacion farmaceutica, y utilizacion de los derivados en la manufactura de medicamentos
IT1271495B (it) Composizione farmaceutica contenente 3-2 (dimetilammino) etil-n-metil-1h-indol-5-metansolfonammide, relativo procedimento di preparazione e impiego della stessa nel trattamento di mammiferi
MX358515B (es) Metodos de uso y composiciones que contienen compuestos inmunomoduladores para el tratamiento y. manejo de sindromes mielodisplasicos.
PE20240881A1 (es) Uso de un inhibidor de la ezh2 en la preparacion de farmacos para el tratamiento del linfoma de linfocitos t
AR037517A1 (es) Derivados de naftiridinas, un proceso para su preparacion, composicion farmaceutica y el uso de los mismos para la preparacion de un medicamento para el tratamiento de una enfermedad inflamatoria
AR038686A1 (es) Formulaciones de derivados de androstano y agonistas del adrenoreceptor beta 2 antiinflamatorios
CO2022017622A2 (es) Inhibidores de quinasa nek7
KR950031074A (ko) 비-펩티드 타키키닌 수용체 길항물질
RU2013121788A (ru) Ингибиторы репликации вич
CY1112376T1 (el) Παραγωγα 2,3,4,9-τετραϋδρο-1η-καρβαζολης ως ανταγωνιστες του υποδοχεα crth2
CO5060477A1 (es) Forma de dosificacion de nefazodona
SE9901573D0 (sv) New compounds
ZA202400988B (en) Aak1 inhibitor and use thereof
UY29085A1 (es) Derivados de pirimidina 4-sulfonamido sustituidos, compuestos intermedios para su preparación, procedimientos de preparación, composiciones medicinales conteniéndolos y aplicaci0nes
EA200601901A1 (ru) Композиции, содержащие иммуномодулирующие соединения для лечения и управления течением миелодиспластических синдромов и способы с их использованием
RU2014119858A (ru) Применение мелатонина для лечения и/или предотвращения мукозита
BR112023026909A2 (pt) Sal farmaceuticamente aceitável de ap1189 ((e)-n-[1-(2-nitrofenil)-1-h-pirrol-2-il-alilidenoamino]-guanidina), composição farmacêutica, forma de dosagem única, e, formulação oral
UY27539A1 (es) Formulación farmacéutica
UY28979A1 (es) Derivados de hidrocloruros de 3-carboxamida, composiciones farmacéuticas que los contienen, procedimiento de preparación y su uso, útiles como inhibidores selectivos de gsk3
NO178336C (no) Analogifremgangsmåte for fremstilling av en terapeutisk aktiv benzimidazolforbindelse og mellomprodukter
CR10210A (es) Derivados de benzoisoindol para el tratamiento del dolor
AR124542A1 (es) Métodos de tratamiento
UY26459A1 (es) 3,4-dihidroquinazolinas 5,6-disustituidas
EA200600377A1 (ru) Новая композиция
BRPI0418743A (pt) métodos de tratamento, prevenção ou controle de uma sìndrome mielodisplásica, de redução ou evitação de um efeito adverso associado com a administração de um segundo ingrediente ativo em um paciente sofrendo de uma sìndrome mielodisplásica, composição farmacêutica, forma de dosagem unitária única, e, kit

Legal Events

Date Code Title Description
FB Suspension of granting procedure